Optimized expression and specific activity of IL-12 by directed molecular evolution
- PMID: 12529500
- PMCID: PMC298744
- DOI: 10.1073/pnas.0237327100
Optimized expression and specific activity of IL-12 by directed molecular evolution
Abstract
DNA delivery of IL-12 has shown promise in reducing the toxic side effects associated with administration of recombinant human (h)IL-12 protein while maintaining the ability to inhibit tumor growth and abolish tumor metastases in animal models. We have developed a more potent version of IL-12 by using DNA shuffling and screening to improve its expression in human cells and specific activity on human T cells. The most improved evolved IL-12 (EvIL-12) derived from seven mammalian genes encoding both the p35 and p40 subunits of IL-12 showed a 128-fold improvement in human T cell proliferation compared with native hIL-12 during the initial screening of supernatants from transected cells. When purified hIL-12 and EvIL-12 proteins were compared in vitro in human T cell proliferation and Th1 differentiation assays, it was demonstrated that EvIL-12 exhibited a concomitant 10-fold increase in the specific activity of the protein compared with hIL-12. Furthermore, DNA shuffling improved the level of expression and homogeneity of the heterodimer synthesized by 293 human embryonic kidney cells transfected with EvIL-12 by at least 10-fold. Molecular analysis of the variant revealed strategic placement of amino acid substitutions that potentially may facilitate heterodimer formation and product expression. The enhanced expression and biological activity of EvIL-12 may improve the effectiveness of IL-12 gene-based vaccines and therapeutics without the toxic side effects sometimes associated with hIL-12 protein administration.
Figures






References
-
- Gately M K, Renzetti L M, Magram J, Stern A S, Adorin I L, Gubler U, Presky D H. Annu Rev Immunol. 1998;16:495–521. - PubMed
-
- Trinchieri G, Scott P. Curr Top Microbiol Immunol. 1999;238:57–78. - PubMed
-
- Greenberger M J, Kunkel S, Strieter R, Lukacs N, Bramson J, Gauldie J, Graham F, Hitt M, Danforth J, Standiford T. J Immunol. 1966;157:3006–3012. - PubMed
-
- Silva R, Pais T, Appelberg R. J Immunol. 1998;161:5578–5585. - PubMed
-
- Miller M, Skeen M, Ziegler H. Cell Immunol. 1998;184:92–104. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials